Ticker > Company >

IOL Chem & Pharma share price

IOL Chemicals And Pharmaceuticals Ltd.

NSE: IOLCP BSE: 524164 SECTOR: Pharmaceuticals & Drugs  2.2 L   2.31 K   316

91.81
+0.74 (0.81%)
BSE: Today, 02:56 PM

Price Summary

Today's High

₹ 94.28

Today's Low

₹ 90.99

52 Week High

₹ 107.41

52 Week Low

₹ 57.51

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2694.88 Cr.

Enterprise Value

2585.02 Cr.

No. of Shares

29.35 Cr.

P/E

26.68

P/B

1.6

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  57.49

CASH

142.62 Cr.

DEBT

32.76 Cr.

Promoter Holding

52.62 %

EPS (TTM)

₹  3.44

Sales Growth

-3.8%

ROE

8.69 %

ROCE

12.3%

Profit Growth

-3.26 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-3.8%
3 Year2.73%
5 Year4.82%

Profit Growth

1 Year-3.26%
3 Year-32.72%
5 Year-10.57%

ROE%

1 Year8.69%
3 Year10.28%
5 Year26.17%

ROCE %

1 Year12.3%
3 Year14.37%
5 Year33.08%

Debt/Equity

0.0203

Price to Cash Flow

9.27

Interest Cover Ratio

12.3441

CFO/PAT (5 Yr. Avg.)

1.08710331940557

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 52.62 0.00
Dec 2024 52.62 0.00
Sep 2024 48.19 0.00
Jun 2024 48.19 0.00
Mar 2024 48.19 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 46.87 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 12.3441.
  • The company has an efficient Cash Conversion Cycle of 45.4212 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.08710331940557.
  • The company has a high promoter holding of 52.62%.

 Limitations

  • The company has shown a poor profit growth of -32.7151210799305% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.73441053792856% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 503.92 502.38 525.75 523.3 527.78
Total Expenditure 453.84 451.58 484.19 476.43 464.84
Operating Profit 50.08 50.8 41.56 46.87 62.94
Other Income 7.52 7.38 6.43 4.07 4.52
Interest 3.41 2.15 4.12 4.46 4.03
Depreciation 16.42 16.8 17.93 18.66 18.53
Exceptional Items 0 0 0 0 0
Profit Before Tax 37.77 39.23 25.94 27.82 44.9
Tax 9.58 9.55 6.79 7.27 13.28
Profit After Tax 28.19 29.68 19.15 20.55 31.62
Adjusted EPS (Rs) 0.96 1.01 0.65 0.7 1.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1894.47 1966.98 2184.02 2217.11 2132.79
Total Expenditure 1320.59 1375.14 1927.74 1990.59 1901.27
Operating Profit 573.88 591.84 256.28 226.52 231.52
Other Income 16.02 24.3 32.04 25.57 30.07
Interest 20.93 5.83 8.29 16.47 16.1
Depreciation 35.73 38.92 43.26 46.13 62.85
Exceptional Items 0 0 -13.93 0 0
Profit Before Tax 533.24 571.39 222.84 189.49 182.64
Tax 171.95 126.83 57.18 49.51 47.22
Net Profit 361.29 444.56 165.66 139.98 135.42
Adjusted EPS (Rs.) 12.7 15.14 5.64 4.77 4.61

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 56.89 58.71 58.71 58.71 58.71
Total Reserves 756.65 1201.72 1331.56 1447.84 1552.62
Borrowings 0 0 0 0 0
Other N/C liabilities 79.73 59.11 56.62 58.15 72.89
Current liabilities 453.63 432.8 575.29 502.17 596.85
Total Liabilities 1346.9 1752.34 2022.18 2066.87 2281.07
Assets
Net Block 469.04 512.36 560.64 751.31 932.69
Capital WIP 19.19 48.27 102.03 81.4 99.83
Intangible WIP 0 0 3.17 8.24 1.04
Investments 0 0 0.1 17.71 17.71
Loans & Advances 1.33 17.61 10.77 9.52 23.62
Other N/C Assets 9.43 21.95 204.87 233.36 49.6
Current Assets 847.91 1152.15 1140.6 965.33 1156.58
Total Assets 1346.9 1752.34 2022.18 2066.87 2281.07
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 533.24 571.39 222.84 189.49 182.64
Adjustment 51.93 27.15 33.12 44.42 60.06
Changes in Assets & Liabilities 2.78 -76.51 -102.34 -63.67 90.08
Tax Paid -117.15 -142.25 -62.58 -47.1 -42.02
Operating Cash Flow 470.8 379.78 91.04 123.14 290.76
Investing Cash Flow -184.23 -317.25 -120.62 -119.19 -191.69
Financing Cash Flow -271.89 -58.28 -1.64 -4.11 -92.5
Net Cash Flow 14.68 4.25 -31.22 -0.16 6.57

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 48.19 48.19 48.19 52.62 52.62
maya devi polycot limited... 21.54 21.54 21.54 21.54 21.54
ncvi enterprises limited 15.96 15.96 15.96 15.96 15.96
nm merchantiles private l... - - - - 13.08
varinder gupta 2.04 2.04 2.04 2.04 2.04
nm merchantiles pvt limit... 8.65 8.65 8.65 13.08 -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 51.81 51.81 51.81 47.38 47.38
g consultants and fabrica... - - - - 1.68
llp - - 0.32 0.36 0.25
vasudeva commercials limi... 7.94 7.94 7.94 7.94 7.94
g consultants and fabrica... 1.68 1.68 1.68 1.68 -
enorg limited 4.43 4.43 4.43 - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research Nuvama

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY25
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22

Company News

IOL Chemicals registers Acetic Anhydride with REACH 16 Jun, 12:30 PM IOL Chemicals & Pharmaceuticals informs about outcome of board meeting 17 May, 2:29 PM IOL Chem & Pharma - Quaterly Results 16 May, 7:06 PM IOL Chem & Pharma - Quaterly Results 16 May, 7:06 PM IOL Chemicals secures approval for Ibuprofen from CDE in China 29 Apr, 12:12 PM IOL Chemicals & Pharmaceuticals informs about trading window closure 26 Mar, 11:20 AM IOL Chemicals commences new Unit 11 for Paracetamol production in Punjab 25 Mar, 11:09 AM IOL Chemicals and Pharmaceuticals gets Certificate of Suitability from EDQM 6 Mar, 2:19 PM IOL Chemicals and Pharmaceuticals reports 11% fall in Q3 consolidated net profit 13 Feb, 3:28 PM IOL Chem & Pharma - Quaterly Results 12 Feb, 6:05 PM IOL Chem & Pharma - Quaterly Results 12 Feb, 6:05 PM IOL Chemicals & Pharmaceuticals informs about newspaper publication 2 Jan, 4:48 PM IOL Chemicals & Pharmaceuticals informs about disclosures 26 Nov, 5:24 PM IOL Chemicals and Pharmaceuticals informs about issuance letter of confirmation 21 Nov, 5:06 PM IOL Chem & Pharma - Quaterly Results 14 Nov, 5:00 PM IOL Chemicals and Pharmaceuticals informs about outcome of board meeting 28 Oct, 2:30 PM IOL Chemicals & Pharmaceuticals informs about details of loss of certificate 5 Oct, 11:51 AM IOL Chemicals and Pharmaceuticals reports 35% fall in Q1 consolidated net profit 12 Aug, 12:00 PM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:37 PM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:37 PM IOL Chemicals gets certificate of suitability from EDQM for Valsartan 24 Jul, 11:00 AM IOL Chemicals gets nod to export ‘Fenofibrate API’ in China market 2 Jul, 10:49 AM Iol Chemicals & Pharmaceuticals informs about press release 18 Jun, 2:52 PM IOL Chemicals & Pharmaceuticals informs about schedule of analyst meeting 15 Jun, 3:41 PM IOL Chemicals gets certificate of suitability for ‘Pantoprazole Sodium Sesquihydrate’ 12 Jun, 11:41 AM IOL Chemicals gets CEP certificate for Allopurinol from EDQM 12 Jun, 10:59 AM Iol Chemicals & Pharmaceuticals informs about loss of share certificates 5 Jun, 5:27 PM IOL Chemicals & Pharmaceuticals informs about loss of share certificate 24 May, 11:55 AM IOL Chemicals and Pharmaceuticals informs about loss of share certificate 18 May, 12:41 PM IOL Chem & Pharma - Quaterly Results 14 May, 4:59 PM IOL Chem & Pharma - Quaterly Results 14 May, 4:59 PM IOL Chem & Pharma - Quaterly Results 14 May, 4:59 PM Iol Chemicals & Pharmaceuticals informs about GMP certificate 3 May, 5:12 PM IOL Chemicals and Pharmaceuticals informs about loss of share certificate 24 Apr, 5:33 PM IOL Chemicals completes ANVISA GMP audit of 10 manufacturing units without any observation 19 Mar, 12:30 PM IOL Chemicals gets approval for ‘Metformin Hydrochloride’ from CDE in China 19 Feb, 3:37 PM IOL Chemicals gets nod to wind up ‘M/s IOL Global’ in UK 7 Feb, 3:30 PM IOL Chemicals and Pharmaceuticals reports marginal fall in Q3 consolidated net profit 7 Feb, 2:24 PM IOL Chem & Pharma - Quaterly Results 6 Feb, 6:15 PM IOL Chem & Pharma - Quaterly Results 6 Feb, 6:15 PM IOL Chem & Pharma - Quaterly Results 6 Feb, 6:15 PM Iol Chemicals & Pharmaceuticals informs about analyst meet 13 Dec, 2:36 PM IOL Chem & Pharma - Quaterly Results 8 Nov, 4:06 PM IOL Chem & Pharma - Quaterly Results 8 Nov, 4:06 PM IOL Chem & Pharma - Quaterly Results 8 Nov, 4:06 PM IOL Chemicals and Pharmaceuticals informs about disclosure 28 Sep, 10:16 AM IOL Chemicals and Pharmaceuticals informs about disclosure 28 Sep, 10:16 AM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:05 PM IOL Chem & Pharma - Quaterly Results 9 Aug, 6:05 PM IOL Chemicals & Pharmaceuticals informs about details of loss of certificate 25 Jul, 4:04 PM

IOL Chem & Pharma Stock Price Analysis and Quick Research Report. Is IOL Chem & Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into IOL Chem & Pharma and its performance over the period of time. IOL Chem & Pharma stock price today is Rs 91.84.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. IOL Chem & Pharma cash from the operating activity was Rs 290.76 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. IOL Chem & Pharma has a Debt to Equity ratio of 0.0203 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In IOL Chem & Pharma , the EPS growth was -3.2576 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, IOL Chem & Pharma has OPM of 10.8552647002283 % which is a bad sign for profitability.
     
  • ROE: IOL Chem & Pharma have a poor ROE of 8.6867 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of IOL Chem & Pharma is Rs 91.84. One can use valuation calculators of ticker to know if IOL Chem & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about IOL Chem & Pharma
X